PANACEABIO

** Panacea Biotec PNCA.NS gains 3.4% to 448 rupees

** Co gets letter of award from UNICEF to supply 115 mln doses of its bivalent oral polio vaccine worth ~$15 mln

** Stock on track to extend Tuesday's gains to the day's session; markets were shut on Wednesday for the Christmas holiday

** PNCA up ~168% YTD; set for biggest ever annual rise

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Nov 8 (Reuters) - Panacea Biotec Ltd PNCA.NS:

• TO CONSIDER RAISING OF FUNDS FOR UPTO $20 MILLION

• TO CONSIDER RAISING OF FUNDS VIA EXTERNAL COMMERCIAL BORROWINGS FROM DFC

Source text: ID:nBSE1XZCLt

Further company coverage: PNCA.NS

(([email protected];;))

** Shares of Panacea Biotec PNCA.NS hit upper circuit of 5% at 349.79

** Co reached settlement with Sanofi Healthcare India in suit seeking to restrain Sanofi India's SANO.NS unit from marketing a fully liquid hexavalent vaccine

** SANO will not commercially launch the vaccine in India and withdraw oppositions to PNCA's patent, per the settlement

** SANO shares down 1.1%

** PNCA shares rose on Friday on getting loan to expand vaccine facility capacity

** Stock is on track to rise in eighth straight session if trend holds

** PNCA up ~99% YTD vs ~41% climb in SANO

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

** Shares of Panacea Biotec PNCA.NS up 8.7% to 171.95 rupees

** Stock hits highest level since mid-Jan this year

** The pharma firm and the Indian Council Of Medical Research initiate phase 3 clinical trial in India with dengue vaccine DengiAll

** Stock last up 3.2%, bringing YTD losses to ~2.6%

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

July 1 (Reuters) - Panacea Biotec Ltd PNCA.NS:

• REQUEST FOR ARBITRATION FILED BY HUMAN VACCINE LIMITED LIABILITY COMPANY, RUSSIA

• HV ALLEGED CO IN ALLEGED BREACH OF OBLIGATIONS UNDER TECHNOLOGY TRANSFER AGREEMENT

• CO MAY BE LIABLE TO REFUND $7 MILLION PLUS INTEREST THEREON AS MAY BE AWARDED

Further company coverage: PNCA.NS

(([email protected];))

Feb 1 (Reuters) - Panacea Biotec Ltd PNCA.NS:

• UNIT GOT USFDA COMMUNICATION INDICATING INSPECTION CLASSIFICATION AS OFFICIAL ACTION INDICATED

Further company coverage: PNCA.NS

(([email protected];))

** Shares of Panacea Biotec PNCA.NS rise as much as 8.83% to 177.5 rupees

** Co said on Thursday it received registration of Valganciclovir powder for oral solution in Germany

** The powder is an antiviral used to treat infections caused by viruses

** Co also launched EasyFourPol, a vaccine for tetanus, polio, and other invasive infections

** More than 650,000 shares change hands, 2.9x its 30-day avg

** Including sessions gains, stock up 20% YTD

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Nov 10 (Reuters) - Panacea Biotec Ltd PNCA.NS:

• INDIA'S PANACEA BIOTEC LTD SEPT-QUARTER CONSOL NET LOSS AFTER TAX 82.9 MILLION RUPEES VERSUS PROFIT 157 MILLION RUPEES

• PANACEA BIOTEC LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.43 BILLION RUPEES VERSUS 1.05 BILLION RUPEES

Source text for Eikon: ID:nBSE6NHKzt

Further company coverage: PNCA.NS

(([email protected];))

** Shares of Panacea Biotec PNCA.NS down as much as 5.4% at 162.6 rupees, their biggest intraday pct loss since Sept. 20

** Co on Thursday said the U.S. Food and Drug Administration (USFDA) issued Form 483 with nine observations for its Baddi unit in Himachal Pradesh

** Adds, will respond to the US FDA within the stipulated time and work closely with US FDA to close the said observations.

** Stock up over 18% YTD

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

Oct 5 (Reuters) - Panacea Biotec Ltd PNCA.NS:

• GOT NOTIFICATION FROM INTERNATIONAL COURT OF ARBITRATION, PARIS

• NOTIFICATION ABOUT ARBITRATION PROCEEDING BEING COMMENCED

• REQUEST FOR ARBITRATION FILED BY APOTEX, BASED OUT OF CANADA

• ARBITRATION FOR DISPUTE BETWEEN THE PARTIES

Source text for Eikon: ID:nBSE2PR0W2

Further company coverage: PNCA.NS

(([email protected];))

Sept 12 (Reuters) -

• SERUM INSTITUTE OF INDIA CUTS STAKE IN PANACEA BIOTEC TO 3.06% FROM 5.24% - EXCHANGE FILING

Source text for Eikon: ID:nBSEbwTbNK

Further company coverage: PNCA.NS

(([email protected];;))

Aug 25 (Reuters) - Panacea Biotec Ltd PNCA.NS:

• SERUM INSTITUTE OF INDIA SELLS 2.39% STAKE IN PANACEA BIOTEC- EXCHANGE FILING

Source text for Eikon: ID:nBSE5ttnTF

Further company coverage: PNCA.NS

(([email protected];))

By Rishika Sadam

HYDERABAD, Aug 24 (Reuters) - Vaccine manufacturer Indian Immunologicals Limited (IIL) expects to commercially launch its dengue fever vaccine by early 2026, a top executive said, as the race to develop the country's first such vaccine heats up.

Dengue, a mosquito-borne disease, has over the last few years become a major public health concern in India, with 31,464 dengue cases and 36 related deaths reported between January and July 31, 2023.

While its spread had fallen during the pandemic, there was a 333% surge from 2020 to 2021 and a 21% rise in number of cases between 2021 and 2022, according to the National Center for Vector Borne Diseases Control.

IIL's managing director, K.Anand Kumar, said the vaccine's early-stage trials conducted on about 90 individuals, aged 18-50 years, did not demonstrate any adverse effects.

"We're about to complete Phase 1 trials and will proceed to the next level. All of this will take at least two to three years. So, we are looking at January 2026 for the vaccine's commercial launch," Kumar said.

The early-stage trials are about determining the safety factor and efficacy to a small extent, Kumar said.

U.S.-based National Institute of Health (NIH) has provided IIL with the virus required for developing the vaccine, Kumar added.

Besides IIL, at least two other Indian companies - Serum Institute of India and Panacea Biotec PNCA.NS - are working to develop a dengue vaccine.

Hyderabad-based IIL, which exports animal as well as human vaccines to more than 50 countries, said its mainstay is the manufacturing of rabies vaccines with its sales contributing about 35% of the total.

The company expects to clock in a total revenue of 13 billion rupees in 2023-2024.

(Reporting by Rishika Sadam; Editing by Sohini Goswami)

(([email protected];))

May 30 (Reuters) - Panacea Biotec Ltd PNCA.NS:

• INDIA'S PANACEA BIOTEC LTD MARCH-QUARTER CONSOL NET LOSS AFTER TAX 126.8 MILLION RUPEES VERSUS PROFIT 12.37 BILLION RUPEES

• PANACEA BIOTEC LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.29 BILLION RUPEES VERSUS 1.41 BILLION RUPEES

Source text for Eikon: ID:nBSE6LKzhl

Further company coverage: PNCA.NS

(([email protected];))